SPARCL1 and metabolic dysfunction-associated steatohepatitis: Both NASH groups experienced significant increases in the YAP1, HSPD1, TNF, TEAD2, ITGB1, FOXA2, MMP14, and SMAD4, as well as miR-1205, miR-6881-5p, miR-650, miR-6807-5p, and SPARCL1-1:2 expression.